Last reviewed · How we verify
Compound danshen dripping pills
Compound danshen dripping pills improve blood circulation and reduce blood stasis by promoting vasodilation and inhibiting platelet aggregation.
Compound danshen dripping pills improve blood circulation and reduce blood stasis by promoting vasodilation and inhibiting platelet aggregation. Used for Angina pectoris, Myocardial infarction prevention, Coronary artery disease.
At a glance
| Generic name | Compound danshen dripping pills |
|---|---|
| Also known as | Dantonic® |
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Drug class | Traditional Chinese medicine preparation; antiplatelet/anticoagulant agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This traditional Chinese medicine-derived formulation contains active compounds from Salvia miltiorrhiza (danshen) that act as antiplatelet and anticoagulant agents. The mechanism involves enhancement of microcirculation, reduction of blood viscosity, and prevention of thrombotic events, thereby improving tissue perfusion and oxygen delivery to ischemic areas.
Approved indications
- Angina pectoris
- Myocardial infarction prevention
- Coronary artery disease
Common side effects
- Bleeding or bruising
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment (PHASE4)
- Compound Danshen Dripping Pill for Diabetic Microvascular Angina (PHASE4)
- Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS) (PHASE4)
- Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance (NA)
- Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness (PHASE1, PHASE2)
- Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy (PHASE3)
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (PHASE3)
- Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compound danshen dripping pills CI brief — competitive landscape report
- Compound danshen dripping pills updates RSS · CI watch RSS
- Tasly Pharmaceuticals, Inc. portfolio CI